Literature DB >> 34071283

Chromosomal Instability in Acute Myeloid Leukemia.

Mateus de Oliveira Lisboa1, Paulo Roberto Slud Brofman1, Ana Teresa Schmid-Braz2, Aline Rangel-Pozzo3, Sabine Mai3.   

Abstract

Chromosomal instability (CIN), the increasing rate in which cells acquire new chromosomal alterations, is one of the hallmarks of cancer. Many studies highlighted CIN as an important mechanism in the origin, progression, and relapse of acute myeloid leukemia (AML). The ambivalent feature of CIN as a cancer-promoting or cancer-suppressing mechanism might explain the prognostic variability. The latter, however, is described in very few studies. This review highlights the important CIN mechanisms in AML, showing that CIN signatures can occur largely in all the three major AML types (de novo AML, secondary-AML, and therapy-related-AML). CIN features in AML could also be age-related and reflect the heterogeneity of the disease. Although most of these abnormalities show an adverse prognostic value, they also offer a strong new perspective on personalized therapy approaches, which goes beyond assessing CIN in vitro in patient tumor samples to predict prognosis. Current and emerging AML therapies are exploring CIN to improve AML treatment, which includes blocking CIN or increasing CIN beyond the limit threshold to induce cell death. We argue that the characterization of CIN features, not included yet in the routine diagnostic of AML patients, might provide a better stratification of patients and be extended to a more personalized therapeutic approach.

Entities:  

Keywords:  MYC; TP53; acute myeloid leukemia; aging; aneuploidy; centrosome dysfunction; chromosomal instability; complex karyotype; cytogenetic heterogeneity; synthetic lethality; telomere dysfunction; therapeutic targets

Year:  2021        PMID: 34071283     DOI: 10.3390/cancers13112655

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  249 in total

1.  Short telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia.

Authors:  R T Calado; J N Cooper; H M Padilla-Nash; E M Sloand; C O Wu; P Scheinberg; T Ried; N S Young
Journal:  Leukemia       Date:  2011-10-18       Impact factor: 11.528

2.  Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.

Authors:  Antonella Sistigu; Takahiro Yamazaki; Erika Vacchelli; Kariman Chaba; David P Enot; Julien Adam; Ilio Vitale; Aicha Goubar; Elisa E Baracco; Catarina Remédios; Laetitia Fend; Dalil Hannani; Laetitia Aymeric; Yuting Ma; Mireia Niso-Santano; Oliver Kepp; Joachim L Schultze; Thomas Tüting; Filippo Belardelli; Laura Bracci; Valentina La Sorsa; Giovanna Ziccheddu; Paola Sestili; Francesca Urbani; Mauro Delorenzi; Magali Lacroix-Triki; Virginie Quidville; Rosa Conforti; Jean-Philippe Spano; Lajos Pusztai; Vichnou Poirier-Colame; Suzette Delaloge; Frederique Penault-Llorca; Sylvain Ladoire; Laurent Arnould; Joanna Cyrta; Marie-Charlotte Dessoliers; Alexander Eggermont; Marco E Bianchi; Mikael Pittet; Camilla Engblom; Christina Pfirschke; Xavier Préville; Gilles Uzè; Robert D Schreiber; Melvyn T Chow; Mark J Smyth; Enrico Proietti; Fabrice André; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2014-10-26       Impact factor: 53.440

3.  Overexpression screens identify conserved dosage chromosome instability genes in yeast and human cancer.

Authors:  Supipi Duffy; Hok Khim Fam; Yi Kan Wang; Erin B Styles; Jung-Hyun Kim; J Sidney Ang; Tejomayee Singh; Vladimir Larionov; Sohrab P Shah; Brenda Andrews; Cornelius F Boerkoel; Philip Hieter
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-22       Impact factor: 11.205

4.  MYC-induced human acute myeloid leukemia requires a continuing IL-3/GM-CSF costimulus.

Authors:  Elizabeth Bulaeva; Davide Pellacani; Naoto Nakamichi; Colin A Hammond; Philip A Beer; Alireza Lorzadeh; Michelle Moksa; Annaïck Carles; Misha Bilenky; Sylvain Lefort; Jeremy Shu; Brian T Wilhelm; Andrew P Weng; Martin Hirst; Connie J Eaves
Journal:  Blood       Date:  2020-12-10       Impact factor: 22.113

Review 5.  Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.

Authors:  Miron Prokocimer; Alina Molchadsky; Varda Rotter
Journal:  Blood       Date:  2017-06-12       Impact factor: 22.113

6.  The synergy of Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia.

Authors:  Huihui Zhao; Huayuan Zhu; Jiayu Huang; Yu Zhu; Ming Hong; Han Zhu; Jingjing Zhang; Shan Li; Lijia Yang; Yun Lian; Shuai Wang; Jianping Mao; Yaoyu Chen; Jianyong Li; Sixuan Qian
Journal:  Leuk Res       Date:  2018-01-02       Impact factor: 3.156

7.  Cell cycle control in acute myeloid leukemia.

Authors:  Dominik Schnerch; Jasmin Yalcintepe; Andrea Schmidts; Heiko Becker; Marie Follo; Monika Engelhardt; Ralph Wäsch
Journal:  Am J Cancer Res       Date:  2012-08-20       Impact factor: 6.166

Review 8.  Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies.

Authors:  Mohammad A Jafri; Shakeel A Ansari; Mohammed H Alqahtani; Jerry W Shay
Journal:  Genome Med       Date:  2016-06-20       Impact factor: 11.117

9.  Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.

Authors:  S Greg Call; Ryan P Duren; Anil K Panigrahi; Loc Nguyen; Pablo R Freire; Sandra L Grimm; Cristian Coarfa; Orla M Conneely
Journal:  Sci Rep       Date:  2020-02-18       Impact factor: 4.379

10.  Detectable clonal mosaicism from birth to old age and its relationship to cancer.

Authors:  Cathy C Laurie; Cecelia A Laurie; Kenneth Rice; Kimberly F Doheny; Leila R Zelnick; Caitlin P McHugh; Hua Ling; Kurt N Hetrick; Elizabeth W Pugh; Chris Amos; Qingyi Wei; Li-e Wang; Jeffrey E Lee; Kathleen C Barnes; Nadia N Hansel; Rasika Mathias; Denise Daley; Terri H Beaty; Alan F Scott; Ingo Ruczinski; Rob B Scharpf; Laura J Bierut; Sarah M Hartz; Maria Teresa Landi; Neal D Freedman; Lynn R Goldin; David Ginsburg; Jun Li; Karl C Desch; Sara S Strom; William J Blot; Lisa B Signorello; Sue A Ingles; Stephen J Chanock; Sonja I Berndt; Loic Le Marchand; Brian E Henderson; Kristine R Monroe; John A Heit; Mariza de Andrade; Sebastian M Armasu; Cynthia Regnier; William L Lowe; M Geoffrey Hayes; Mary L Marazita; Eleanor Feingold; Jeffrey C Murray; Mads Melbye; Bjarke Feenstra; Jae H Kang; Janey L Wiggs; Gail P Jarvik; Andrew N McDavid; Venkatraman E Seshan; Daniel B Mirel; Andrew Crenshaw; Nataliya Sharopova; Anastasia Wise; Jess Shen; David R Crosslin; David M Levine; Xiuwen Zheng; Jenna I Udren; Siiri Bennett; Sarah C Nelson; Stephanie M Gogarten; Matthew P Conomos; Patrick Heagerty; Teri Manolio; Louis R Pasquale; Christopher A Haiman; Neil Caporaso; Bruce S Weir
Journal:  Nat Genet       Date:  2012-05-06       Impact factor: 38.330

View more
  1 in total

1.  Case of Patient with AML with Complex Karyotype including Ultra-Rare t(4;8)(q32;q13), t(4;11)(q21;p15) and Familial Aggregation of Myeloid Malignancies.

Authors:  Sławomir Milczarek; Ewa Studniak; Bartłomiej Baumert; Michał Janowski; Wioleta Bonda; Joanna Pietrzak; Aleksandra Łanocha; Edyta Paczkowska; Barbara Zdziarska; Bogusław Machaliński
Journal:  Medicina (Kaunas)       Date:  2022-01-10       Impact factor: 2.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.